Key Characteristics
- Inpharma looks beyond the borders of the USA for promising biotech companies. We have partnerships around the world, largely in South America, Africa, and Southeast Asia, and we look to expand our network even further.
- We invest heavily in the life sciences, specifically biotechnology. Our portfolio companies have roots in biopharmaceutical, immunology, molecular targeting, and cell therapy.
- Potential biotech companies should possess proprietary innovations that address a critical medical need. Alternatively, we do consider companies that are able to demonstrate progress towards developing these breakthroughs.
Company Profile
- While we generally invest in seed stage companies, we are flexible to the point of entry. We have invested in preclinical and clinical stage assets, both private and public.
- We typically prefer leading investment rounds, though we are not opposed to take a follower investor role in larger rounds.
- Companies should have a comprehensive business plan spanning 3-5 years, complete with developmental and testing milestones.
- This strategy should also outline the status of any intellectual property as well as any known third-party intellectual properties that may run conflict to future developments.
Company Culture
- Potential companies should share our values at Inpharma. They should demonstrate innovation in ideas and strategies, be open to collaboration, and be passionate about advancing biotechnology and its global impact.
- While we recognize that a management team is seldom complete, we like to see an ambitious and business-savvy management team, complete with a scientific background. If a company's management team requires additional members for completion, it's vital that the team demonstrates flexibility and accommodates new members.
Our Strategy
- Inpharma offers business management and consulting services to aid in the growth and development of our portfolio companies.
- We are active investors. Our team possesses the experience and skills to work alongside our portfolio companies. We afford them any resources necessary to accomplish their goals and expect transparency and mutual respect in return.
- Inpharma typically exits within 5-8 years. We work diligently with our portfolio companies to ensure a smooth transition in accordance with their founder's vision.
Do You Have More Questions?
We're here to answer them. Please feel free to contact us directly for more information specific to your company's individual needs and goals.